Driehaus Capital Management LLC Purchases Shares of 2,589,553 Septerna, Inc. (NASDAQ:SEPN)

Driehaus Capital Management LLC acquired a new position in Septerna, Inc. (NASDAQ:SEPN) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,589,553 shares of the company’s stock, valued at approximately $59,301,000. Driehaus Capital Management LLC owned approximately 5.83% of Septerna as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC bought a new stake in Septerna in the fourth quarter valued at about $25,000. New York State Common Retirement Fund acquired a new position in Septerna during the fourth quarter worth $32,000. Legal & General Group Plc acquired a new position in shares of Septerna during the 4th quarter worth about $42,000. Summit Investment Advisors Inc. bought a new stake in shares of Septerna during the 4th quarter worth approximately $45,000. Finally, BNP Paribas Financial Markets acquired a new stake in Septerna in the fourth quarter valued at $52,000.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $50.00 target price on shares of Septerna in a research note on Tuesday, February 11th. Wells Fargo & Company lowered their target price on Septerna from $14.00 to $11.00 and set an “equal weight” rating for the company in a research report on Friday, March 28th.

Septerna Price Performance

Shares of Septerna stock opened at $7.05 on Thursday. The company has a 50-day moving average price of $6.15. Septerna, Inc. has a one year low of $4.17 and a one year high of $28.99.

Septerna (NASDAQ:SEPN) last posted its earnings results on Thursday, March 27th. The company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.05. The business had revenue of $0.21 million during the quarter, compared to analyst estimates of $0.13 million. Analysts expect that Septerna, Inc. will post -7.11 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Gil M. Labrucherie purchased 6,282 shares of the business’s stock in a transaction dated Tuesday, February 25th. The stock was purchased at an average cost of $5.59 per share, with a total value of $35,116.38. Following the completion of the acquisition, the chief financial officer now directly owns 36,282 shares of the company’s stock, valued at approximately $202,816.38. The trade was a 20.94 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Alan Ezekowitz acquired 7,491 shares of Septerna stock in a transaction that occurred on Tuesday, March 4th. The shares were purchased at an average cost of $6.35 per share, with a total value of $47,567.85. Following the purchase, the director now owns 24,911 shares of the company’s stock, valued at $158,184.85. This represents a 43.00 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought 74,346 shares of company stock valued at $439,670 in the last three months.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.